![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 4
Zeitschriftenartikel
Turner, N. C.; Slamon, D. J.; Ro, J.; Bondarenko, I; Im, S-A; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Andre, F.; Puyana Theall, K.; Huang, X.; Giorgetti, C.; Huang Bartlett, C. und Cristofanilli, M.
(2018):
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.
In: New England Journal of Medicine, Bd. 379, Nr. 20: S. 1926-1936
Verma, S.; DeMichele, A. M.; Loi, S.; Ro, J.; Colleoni, M.; Iwata, H.; Harbeck, N.; Stearns, V.; Cristofanilli, M.; Huang Bartlett, C.; Schnell, P.; Zhang, K.; Thiele, A.; Turner, N. C. und Rugo, H. S.
(2016):
Updated safety from a double-blind phase 3 trial (PALOMA-3) of fulvestrant with placebo or with palbociclib in pre- and postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy.
In: Cancer Research, Bd. 76
Harbeck, N.; Iyer, S.; Turner, N.; Cristofanilli, M.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Bhattacharyya, H.; Theall, K. Puyana; Bartlett, C. H. und Loibl, S.
(2016):
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.
In: Annals of Oncology, Bd. 27, Nr. 6: S. 1047-1054
Loibl, S.; Demichele, A.; Turner, N. M.; Cristofanilli, M.; Loi, S.; Verma, S.; Bhattacharyya, H.; Ke, Z.; Giorgetti, C.; Bartlett, C. H.; Iyer, S.; Colleoni, M.; Masuda, N.; Im, S.-A. und Harbeck, N.
(2016):
Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2-metastatic breast cancer.
In: Annals of Oncology, Bd. 27